DSMA Stock Overview Provides solutions for nutrition, health, and beauty businesses in the Switzerland, Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
DSM-Firmenich AG Competitors Price History & Performance
Summary of share price highs, lows and changes for DSM-Firmenich Historical stock prices Current Share Price €114.50 52 Week High €157.35 52 Week Low €105.88 Beta 0.72 1 Month Change -3.27% 3 Month Change -3.54% 1 Year Change -27.23% 3 Year Change -3.29% 5 Year Change 29.12% Change since IPO 161.12%
Recent News & Updates
DSM-Firmenich AG, Annual General Meeting, May 06, 2025 Nov 01
Lesaffre et Compagnie, SA completed the acquisition of Yeast Extract Business of DSM-Firmenich. Oct 03 KD Pharma Group SA completed the acquisition of MEG-3® fish oil business of dsm-firmenich from DSM-Firmenich AG (ENXTAM:DSFIR). Oct 01
DSM-Firmenich AG to Report Fiscal Year 2024 Results on Feb 13, 2025 Jul 31 Dsm-Firmenich Ag Approves Retirement of Pradeep Pant from the Board
Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR). Mar 08 See more updates
DSM-Firmenich AG, Annual General Meeting, May 06, 2025 Nov 01
Lesaffre et Compagnie, SA completed the acquisition of Yeast Extract Business of DSM-Firmenich. Oct 03 KD Pharma Group SA completed the acquisition of MEG-3® fish oil business of dsm-firmenich from DSM-Firmenich AG (ENXTAM:DSFIR). Oct 01
DSM-Firmenich AG to Report Fiscal Year 2024 Results on Feb 13, 2025 Jul 31 Dsm-Firmenich Ag Approves Retirement of Pradeep Pant from the Board
Jingjiang Cosfocus Health Technology Co., Ltd. acquired DSM Jiangshan Pharmaceutical (Jiangsu) Co., Ltd from DSM-Firmenich AG (ENXTAM:DSFIR). Mar 08
DSM-Firmenich AG Proposes Dividend for the Financial Year 2023 Feb 15
DSM-Firmenich AG to Report First Half, 2024 Results on Jul 30, 2024 Jan 19
DSM-Firmenich Makes Voluntary Cash Offer for DSM Shares Jan 09
DSM-Firmenich AG, Annual General Meeting, May 07, 2024 Oct 31
dsm-firmenich Achieves Regulatory Clearance in China for Two HMO Ingredients for Early Life Nutrition Oct 10
DSM-Firmenich AG to Report Fiscal Year 2023 Results on Feb 15, 2024 Aug 03 DSM-Firmenich AG (ENXTAM:DSFIR) acquired Adare BIOME from Adare Pharmaceuticals, Inc. for enterprise value of €280 million. Jul 04
DSM-Firmenich AG has completed a Follow-on Equity Offering in the amount of €733.264232 million. May 26
Key Executive recently sold €438k worth of stock Apr 05
Full year 2022 earnings released: EPS: €2.63 (vs €6.25 in FY 2021) Feb 20
DSM Firmenich Announces Intention Pay Final Gross Dividend Feb 18
Key Executive recently bought €587k worth of stock Nov 16
Royal DSM NV Sponsored ADR to Be Deleted from OTC Equity Nov 14
Koninklijke DSM N.V. to Report Fiscal Year 2022 Results on Feb 16, 2023 Nov 01 Avient Corporation (NYSE:AVNT) completed the acquisition of Protective Materials business of Koninklijke DSM N.V. (ENXTAM:DSM)
First half 2022 earnings released: EPS: €1.68 (vs €2.41 in 1H 2021) Aug 03
Koninklijke DSM N.V. Announces Interim Dividend Aug 02 Koninklijke DSM N.V. (ENXTAM:DSM) agrees to acquire Prodap Participacoes S/A. Jun 08
Advent International Corporation and LANXESS Aktiengesellschaft (XTRA:LXS) agreed to acquire Engineering Materials business of Royal DSM from Koninklijke DSM N.V. (ENXTAM:DSM) for €3.9 billion. Koninklijke DSM N.V. Declares Dividend for the Financial Year 2021, Payable as from 3 June 2022 May 12
Public Joint Stock Company KuibyshevAzot (MISX:KAZT) acquired Volgaplast Compounding Ltd from Koninklijke DSM N.V. (ENXTAM:DSM) for RUB119 million.
Upcoming dividend of €1.70 per share May 05
Koninklijke DSM N.V. Reaffirms Earnings Guidance for the Year 2022 May 03
Avient Corporation (NYSE:AVNT) entered into agreement to acquire Protective Materials business of Koninklijke DSM N.V. (ENXTAM:DSM) for €1.4 billion ($1.5 billion). Apr 21
Avient Corporation (NYSE:AVNT) eneteed into agreement to acquire Protective Materials business of DSM Apr 20
DSM receives landmark EU market approval for its methane-reducing feed additive Bovaer Feb 24 Royal DSM Proposes Dividend Increase
Lanxess Reportedly Teams Up with Advent to Bid for DSM's Materials Ops Feb 01
Koninklijke DSM N.V. (ENXTAM:DSM) completed the acquisition of Vestkorn Milling AS. Dec 18
Koninklijke DSM N.V. (ENXTAM:DSM) signed an agreement to acquire Vestkorn Milling As for an enterprise value of €65 million. Nov 30
Koninklijke DSM N.V. Receives First Full Market Authorizations for Methane-Reducing Feed Additive Bovaer® for Beef and Dairy in Brazil and Chile Sep 10
Independent Deputy Chairwoman of Supervisory Board has left the company May 12
Independent Chairman of Supervisory Board Robert Routs has left the company May 12
Royal DSM Declares Final Dividend for the Financial Year 2020, Payable from 1 June 2021 May 07
Upcoming dividend of €1.60 per share May 03
Key Executive recently sold €750k worth of stock Apr 04
Worthen Industries, Inc. agreed to acquire Advanced Solar Backsheets Business of Koninklijke DSM N.V. from Koninklijke DSM N.V. (ENXTAM:DSM). Mar 12
Koninklijke Dsm N.V. Announces Board Changes Mar 05
Full year 2020 earnings released: EPS €2.64 (vs €4.27 in FY 2019) Feb 20
Revenue misses expectations Feb 20
Royal DSM Announces Executive Changes Jan 21
Valio and Royal Dsm Announces Collaboration Agreement to Develop Sustainable Dairy Products Dec 15
DSM Suspends Overall Earnings Outlook for the Full Year 2020 Nov 04 Koninklijke DSM N.V. (ENXTAM:DSM) completed the acquisition of ERBER Group from Erber It Service GmbH, San Pacific Investments Pte Ltd. and San Venture Pte. ltd.
Covestro AG (XTRA:1COV) reached an agreement to acquire Resins & Functional Materials and associated businesses from Koninklijke DSM N.V. (ENXTAM:DSM) for purchase price of €1.6 billion. Oct 02 Würth Industry North America Signs Agreement with DSM To Nationally Distribute DSM 3D Printing Material Solutions Koninklijke DSM N.V. to Report Q1, 2021 Results on May 05, 2021 Koninklijke DSM N.V. completed the acquisition of 100% stake in Pocketcoach GmbH. Shareholder Returns DSMA GB Chemicals GB Market 7D 0% -2.0% -1.4% 1Y -27.2% -24.0% 4.6%
See full shareholder returns
Return vs Market: DSMA underperformed the UK Market which returned -2.4% over the past year.
Price Volatility Is DSMA's price volatile compared to industry and market? DSMA volatility DSMA Average Weekly Movement n/a Chemicals Industry Average Movement 5.8% Market Average Movement 4.9% 10% most volatile stocks in GB Market 10.3% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: DSMA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DSMA's volatility change over the past year.
About the Company DSM-Firmenich AG, a science-based company, engages in health and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Animal Nutrition & Health (ANH); Health, Nutrition & Care (HNC); and Food & Beverage segments. The Animal Nutrition & Health segment offers essential products, including vitamins, premixes, and carotenoids; performance solutions, such as enzymes, microbes, and eubiotics; precision services comprising support with data analysis to measure animal health and environmental footprint on farm level and feed safety; and methane reducing feed additive for ruminants.
Show more DSM-Firmenich AG Fundamentals Summary How do DSM-Firmenich's earnings and revenue compare to its market cap? DSMA fundamental statistics Market cap €763.73m Earnings (TTM ) €454.00m Revenue (TTM ) €8.39b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) DSMA income statement (TTM ) Revenue €8.39b Cost of Revenue €5.70b Gross Profit €2.69b Other Expenses €2.24b Earnings €454.00m
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
Aug 02, 2023
Earnings per share (EPS) 67.80 Gross Margin 32.06% Net Profit Margin 5.41% Debt/Equity Ratio 26.6%
How did DSMA perform over the long term?
See historical performance and comparison Dividends
2.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/05/31 08:25 End of Day Share Price 2023/05/02 00:00 Earnings 2022/12/31 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources DSM-Firmenich AG is covered by 61 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mutlu Gundogan ABN AMRO Bank N.V. Martin Schnee AlphaValue Volker Bosse Baader Helvea Equity Research
Show 58 more analysts 
